A5052597763- Medical Imaging Techniques and Applications
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Radiation Dose and Imaging
- CNS Lymphoma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Cardiac Imaging and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Medical Imaging and Pathology Studies
- Lung Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- Advanced X-ray and CT Imaging
- Advanced MRI Techniques and Applications
- Hematological disorders and diagnostics
- Sarcoma Diagnosis and Treatment
- MRI in cancer diagnosis
- Ovarian cancer diagnosis and treatment
- Cancer, Hypoxia, and Metabolism
- Occupational and environmental lung diseases
- Epilepsy research and treatment
- Head and Neck Cancer Studies
- Thyroid Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
King's College London
2016-2025
Kings Health Partners
2016-2025
St Thomas' Hospital
2015-2024
St. Thomas Hospital
2000-2024
King's College Hospital
1998-2023
The London College
2012-2023
King's College - North Carolina
2022
European Organisation for Research and Treatment of Cancer
2021
Health Affairs
2021
University of Manchester
2019
The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment patients with Hodgkin lymphoma (HL) non-Hodgkin (NHL). A workshop held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 2011, that included leading hematologists, oncologists, radiation pathologists, radiologists, nuclear medicine physicians, representing major international clinical trials groups cancer centers. Clinical imaging subcommittees...
The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results FDG PET/CT for oncological imaging adult patients. PET a quantitative technique therefore requires common quality control (QC)/quality assurance (QA) procedure maintain accuracy precision quantitation. Repeatability reproducibility are two essential requirements any measurement and/or biomarker. relates uncertainty obtaining same result patient when he or she examined...
Recent advances in imaging, use of prognostic indices, and molecular profiling techniques have the potential to improve disease characterization outcomes lymphoma. International trials are under way test image-based response–adapted treatment guided by early interim positron emission tomography (PET)–computed (CT). Progress imaging is influencing trial design affecting clinical practice. In particular, a five-point scale grade response using PET-CT, which can be adapted suit requirements for...
We tested interim positron-emission tomography–computed tomography (PET-CT) as a measure of early response to chemotherapy in order guide treatment for patients with advanced Hodgkin’s lymphoma.
It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings on positron-emission tomography (PET) after three cycles of chemotherapy doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) require radiotherapy.
At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts Deauville, France, proposed to develop simple reproducible rules Accordingly, validation study was undertaken with the primary aim of validating prognostic role using Deauville 5-point score evaluate images secondary measuring concordance rates among reviewers same score. This paper focuses on...
The study objectives were to assess the prognostic value of quantitative PET and test whether combining baseline metabolic tumour burden with early response could improve predictive power in DLBCL. A total 147 patients DLBCL underwent FDG-PET/CT scans before after two cycles RCHOP. Quantitative parameters including volume (MTV) lesion glycolysis (TLG) measured, as well percentage change these parameters. Cox regression analysis was used relationship between progression-free survival (PFS)...
A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients Hodgkin lymphoma; (ii) reproducibility Deauville five-point scale for interpretation interim scan. Two hundred sixty newly diagnosed lymphoma were enrolled. Fifty-three early unfavorable 207 advanced-stage disease treated ± involved-field or consolidation...
PURPOSE Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival compare with International Prognostic Index (IPI) its individual components derive prognostic model. METHODS PET scans clinical data included from five published studies newly diagnosed lymphoma. Transformations of compared primary end points 3-year progression-free (PFS) overall (OS) for further...
This guideline is aimed at providing healthcare professionals with clear guidance on the management of patients diffuse large B-cell lymphoma (DLBCL). Disease confined to specific extranodal sites, such as primary central nervous system lymphoma, testicular mediastinal DLBCL leg type, etc., beyond scope this guideline. It not intention provide treatment recommendations for all situations and clinicians are advised make decisions taking into account individual patient circumstances. The group...
One hundred and ninety-three hemato-oncologists nuclear medicine specialists from 23 countries joined the 2-day Third International Workshop on Interim Positon Emission Tomography in Lymphoma held September 2011. Forty scientific posters were presented or discussed plenary session. Final results of international validation studies Deauville criteria change maximum standardized uptake value (ΔSUV(MAX)) analysis Hodgkin lymphoma (HL) as well non-Hodgkin (NHL) reported. These confirmatory...
Summary Interim 2‐[18F]Fluoro‐2‐deoxy‐D‐glucose Positron Emission Tomography performed after two chemotherapy cycles (PET‐2) is the most reliable predictor of treatment outcome in ABVD‐treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed a therapeutic strategy based on PET‐2 results: positive patients switched to BEACOPP, while negative continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL admitted nine centres were enrolled; 54 patients, unfit...
Increased tumor burden is associated with inferior outcomes in many lymphoma subtypes. Surrogates of that are easy to measure, such as the maximum dimension bulkiest lesion on CT, have been used prognostic indices for years. Recently, total metabolic volume (MTV) and glycolysis emerged promising robust biomarkers outcome various lymphomas. The median MTV optimal cutoffs separate patients into risk groups a study population are, however, highly dependent characteristics delineation method...